{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:20Z","timestamp":1792783520481,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571467"],"award-info":[{"award-number":["82571467"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["JQ24058"],"award-info":[{"award-number":["JQ24058"]}]},{"name":"Beijing Municipal Science & Technology Committee","award":["Z211100003521019"],"award-info":[{"award-number":["Z211100003521019"]}]},{"name":"Outstanding Young Investigator Program of Capital Medical University","award":["A2402"],"award-info":[{"award-number":["A2402"]}],"id":[{"id":"https:\/\/ror.org\/013xs5b60","id-type":"ROR","asserted-by":"crossref"}]},{"name":"China Shijiazhuang Pharmaceutical Company Recomgen Pharmaceutical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01060-5","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:32:17Z","timestamp":1792143137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neutrophil to Lymphocyte Ratio and Neurological Outcome in Ischemic Stroke at 4.5 to 24\u00a0Hours: A Post Hoc Analysis of TRACE-III Trial"],"prefix":"10.1007","author":[{"given":"Manjun","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe Kang","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce C. V.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee H.","family":"Schwamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anding","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangzhe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1353-2295","authenticated-orcid":false,"given":"Yunyun","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"12","key":"1060_CR1","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"WJ Powers","year":"2019","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association\/American Stroke Association. Stroke. 2019;50(12):e344\u2013418.","journal-title":"Stroke"},{"issue":"16","key":"1060_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1161\/CIRCULATIONAHA.122.063366","volume":"147","author":"KS Asif","year":"2023","unstructured":"Asif KS, Otite FO, Desai SM, et al. Mechanical thrombectomy global access for stroke (MT-GLASS): a mission thrombectomy (MT-2020 Plus) study. Circulation. 2023;147(16):1208\u201320.","journal-title":"Circulation"},{"issue":"9","key":"1060_CR3","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1073\/pnas.91.9.3670","volume":"91","author":"BA Keyt","year":"1994","unstructured":"Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA. 1994;91(9):3670\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10377","key":"1060_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","volume":"401","author":"Y Wang","year":"2023","unstructured":"Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase\u00a03, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet. 2023;401(10377):645\u201354.","journal-title":"Lancet"},{"issue":"10347","key":"1060_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","volume":"400","author":"BK Menon","year":"2022","unstructured":"Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161\u20139.","journal-title":"Lancet"},{"issue":"7","key":"1060_CR6","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1161\/STROKEAHA.111.644963","volume":"43","author":"D Tong","year":"2012","unstructured":"Tong D, Reeves MJ, Hernandez AF, et al. Times from symptom onset to hospital arrival in the Get with the Guidelines-Stroke Program 2002 to 2009: temporal trends and implications. Stroke. 2012;43(7):1912\u20137.","journal-title":"Stroke"},{"issue":"11","key":"1060_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S1474-4422(19)30078-X","volume":"18","author":"K Shi","year":"2019","unstructured":"Shi K, Tian DC, Li ZG, Ducruet AF, Lawton MT, Shi FD. Global brain inflammation in stroke. Lancet Neurol. 2019;18(11):1058\u201366.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1060_CR8","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1161\/CIRCRESAHA.121.319994","volume":"130","author":"M Endres","year":"2022","unstructured":"Endres M, Moro MA, Nolte CH, Dames C, Buckwalter MS, Meisel A. Immune pathways in etiology, acute phase, and chronic sequelae of ischemic stroke. Circ Res. 2022;130(8):1167\u201386.","journal-title":"Circ Res"},{"key":"1060_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678744","volume":"12","author":"YM Qiu","year":"2021","unstructured":"Qiu YM, Zhang CL, Chen AQ, et al. Immune cells in the BBB disruption after acute ischemic stroke: targets for immune therapy? Front Immunol. 2021;12:678744.","journal-title":"Front Immunol"},{"issue":"1","key":"1060_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCRESAHA.120.317596","volume":"128","author":"K Shi","year":"2021","unstructured":"Shi K, Zou M, Jia DM, et al. tPA mobilizes immune cells that exacerbate hemorrhagic transformation in stroke. Circ Res. 2021;128(1):62\u201375.","journal-title":"Circ Res"},{"issue":"2","key":"1060_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.atherosclerosis.2009.07.041","volume":"208","author":"M Blanco","year":"2010","unstructured":"Blanco M, Sobrino T, Montaner J, et al. Stroke with polyvascular atherothrombotic disease. Atherosclerosis. 2010;208(2):587\u201392.","journal-title":"Atherosclerosis"},{"issue":"8","key":"1060_CR12","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/STROKEAHA.118.021477","volume":"49","author":"N Goyal","year":"2018","unstructured":"Goyal N, Tsivgoulis G, Chang JJ, et al. Admission neutrophil-to-lymphocyte ratio as a prognostic biomarker of outcomes in large vessel occlusion strokes. Stroke. 2018;49(8):1985\u20137.","journal-title":"Stroke"},{"issue":"9","key":"1060_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3162","volume":"13","author":"Q Wu","year":"2023","unstructured":"Wu Q, Chen HS. Neutrophil-to-lymphocyte ratio and its changes predict the 3-month outcome and mortality in acute ischemic stroke patients after intravenous thrombolysis. Brain Behav. 2023;13(9):e3162.","journal-title":"Brain Behav"},{"issue":"1","key":"1060_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02090-6","volume":"18","author":"P Gong","year":"2021","unstructured":"Gong P, Liu Y, Gong Y, et al. The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke. J Neuroinflammation. 2021;18(1):51.","journal-title":"J Neuroinflammation"},{"issue":"7","key":"1060_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/neurintsurg-2020-016342","volume":"13","author":"M Aly","year":"2021","unstructured":"Aly M, Abdalla RN, Batra A, et al. Follow-up neutrophil-lymphocyte ratio after stroke thrombectomy is an independent biomarker of clinical outcome. J Neurointerv Surg. 2021;13(7):609\u201313.","journal-title":"J Neurointerv Surg"},{"issue":"3","key":"1060_CR16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1161\/STROKEAHA.120.032130","volume":"52","author":"D Ferro","year":"2021","unstructured":"Ferro D, Matias M, Neto J, et al. Neutrophil-to-lymphocyte ratio predicts cerebral edema and clinical worsening early after reperfusion therapy in stroke. Stroke. 2021;52(3):859\u201367.","journal-title":"Stroke"},{"issue":"1","key":"1060_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85373-5","volume":"11","author":"Y Bi","year":"2021","unstructured":"Bi Y, Shen J, Chen SC, Chen JX, Xia YP. Prognostic value of neutrophil to lymphocyte ratio in acute ischemic stroke after reperfusion therapy. Sci Rep. 2021;11(1):6177.","journal-title":"Sci Rep"},{"issue":"10","key":"1060_CR18","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1161\/STROKEAHA.123.044123","volume":"54","author":"Q Liu","year":"2023","unstructured":"Liu Q, Shi K, Wang Y, Shi FD. Neurovascular inflammation and complications of thrombolysis therapy in stroke. Stroke. 2023;54(10):2688\u201397.","journal-title":"Stroke"},{"issue":"1","key":"1060_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02222-8","volume":"21","author":"C Wang","year":"2021","unstructured":"Wang C, Zhang Q, Ji M, Mang J, Xu Z. Prognostic value of the neutrophil-to-lymphocyte ratio in acute ischemic stroke patients treated with intravenous thrombolysis: a systematic review and meta-analysis. BMC Neurol. 2021;21(1):191.","journal-title":"BMC Neurol"},{"issue":"3","key":"1060_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2402980","volume":"391","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Campbell BCV, Schwamm LH, et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy. N Engl J Med. 2024;391(3):203\u201312.","journal-title":"N Engl J Med"},{"issue":"1","key":"1060_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/svn-2023-002310","volume":"9","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Campbell BCV, Fisher M, et al. Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase\u00a0III, open-label, controlled trial. Stroke Vasc Neurol. 2024;9(1):82\u20139.","journal-title":"Stroke Vasc Neurol"},{"issue":"4","key":"1060_CR22","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s40120-022-00409-w","volume":"11","author":"Y Xiong","year":"2022","unstructured":"Xiong Y, Luo Y, Wang M, et al. Evaluation of diffusion-perfusion mismatch in acute ischemic stroke with a new automated perfusion-weighted imaging software: a retrospective study. Neurol Ther. 2022;11(4):1777\u201388.","journal-title":"Neurol Ther"},{"issue":"6","key":"1060_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1136\/svn-2023-002964","volume":"9","author":"Z Cao","year":"2024","unstructured":"Cao Z, Wang D, Feng X, et al. Assessment of perfusion volumes by a new automated software for computed tomography perfusion. Stroke Vasc Neurol. 2024;9(6):693\u20138.","journal-title":"Stroke Vasc Neurol"},{"issue":"13","key":"1060_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","volume":"359","author":"W Hacke","year":"2008","unstructured":"Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u201329.","journal-title":"N Engl J Med"},{"issue":"11","key":"1060_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3261","volume":"13","author":"C Xu","year":"2023","unstructured":"Xu C, Cai L, Yi T, Yi X, Hu Y. Neutrophil-to-lymphocyte ratio is associated with stroke progression and functional outcome in patients with ischemic stroke. Brain Behav. 2023;13(11):e3261.","journal-title":"Brain Behav"},{"issue":"1","key":"1060_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12028-019-00859-5","volume":"33","author":"A Giede-Jeppe","year":"2020","unstructured":"Giede-Jeppe A, Mad\u017ear D, Sembill JA, et al. Increased neutrophil-to-lymphocyte ratio is associated with unfavorable functional outcome in acute ischemic stroke. Neurocrit Care. 2020;33(1):97\u2013104.","journal-title":"Neurocrit Care"},{"issue":"1","key":"1060_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/00207454.2024.2414280","volume":"136","author":"M Zhang","year":"2026","unstructured":"Zhang M, Zhao W, Wu C, et al. Inflammation index in failure of delay functional independence after successful recanalization. Int J Neurosci. 2026;136(1):7\u201314.","journal-title":"Int J Neurosci"},{"key":"1060_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1496628","volume":"15","author":"W Gao","year":"2024","unstructured":"Gao W, Annadurdyyev A, Yu L, et al. Day\u00a03 neutrophil-to-lymphocyte ratio and its derived indices predict 90-day poor outcomes following mechanical thrombectomy in acute ischemic stroke patients. Front Neurol. 2024;15:1496628.","journal-title":"Front Neurol"},{"key":"1060_CR29","doi-asserted-by":"crossref","unstructured":"Long L, Tang S, Chen L, Tian M, Li P, Zhang H. Association between neutrophil-to-lymphocyte ratio and functional outcomes in patients with large vessel occlusion stroke treated with endovascular thrombectomy. BMC Neurol. 2026;26(1):262.","DOI":"10.1186\/s12883-026-04746-3"},{"issue":"12","key":"1060_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.71122","volume":"15","author":"JY Li","year":"2025","unstructured":"Li JY, Li J, Lu ZJ, et al. Neutrophil-to-lymphocyte ratio as an independent predictor of adverse short-term functional outcomes after reperfusion therapy in acute ischemic stroke. Brain Behav. 2025;15(12):e71122.","journal-title":"Brain Behav"},{"key":"1060_CR31","doi-asserted-by":"publisher","unstructured":"Xiang Z, Yuan X, Wan J, et al. Neutrophil-to-lymphocyte ratio predicts prognosis after endovascular thrombectomy in acute ischemic stroke: a meta-analysis. Curr Neurovasc Res. 2026. https:\/\/doi.org\/10.2174\/0115672026480618260618043654.","DOI":"10.2174\/0115672026480618260618043654"},{"issue":"1","key":"1060_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0680-x","volume":"13","author":"Z Guo","year":"2016","unstructured":"Guo Z, Yu S, Xiao L, et al. Dynamic change of neutrophil to lymphocyte ratio and hemorrhagic transformation after thrombolysis in stroke. J Neuroinflammation. 2016;13(1):199.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"1060_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1161\/STROKEAHA.119.024157","volume":"51","author":"NS Parikh","year":"2020","unstructured":"Parikh NS, Merkler AE, Iadecola C. Inflammation, autoimmunity, infection, and stroke: epidemiology and lessons from therapeutic intervention. Stroke. 2020;51(3):711\u20138.","journal-title":"Stroke"},{"key":"1060_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-17","volume":"9","author":"E Kenne","year":"2012","unstructured":"Kenne E, Erlandsson A, Lindbom L, Hillered L, Clausen F. Neutrophil depletion reduces edema formation and tissue loss following traumatic brain injury in mice. J Neuroinflammation. 2012;9:17.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"1060_CR35","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/STROKEAHA.117.019896","volume":"49","author":"C Ducroux","year":"2018","unstructured":"Ducroux C, Di Meglio L, Loyau S, et al. Thrombus neutrophil extracellular traps content impair tPA-induced thrombolysis in acute ischemic stroke. Stroke. 2018;49(3):754\u20137.","journal-title":"Stroke"},{"issue":"5","key":"1060_CR36","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1161\/01.STR.29.5.1020","volume":"29","author":"AM Romanic","year":"1998","unstructured":"Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998;29(5):1020\u201330.","journal-title":"Stroke"},{"issue":"7738","key":"1060_CR37","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-018-0824-5","volume":"565","author":"M Ito","year":"2019","unstructured":"Ito M, Komai K, Mise-Omata S, et al. Brain regulatory T\u00a0cells suppress astrogliosis and potentiate neurological recovery. Nature. 2019;565(7738):246\u201350.","journal-title":"Nature"},{"issue":"3","key":"1060_CR38","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.18632\/aging.102752","volume":"12","author":"WB Zhang","year":"2020","unstructured":"Zhang WB, Zeng YY, Wang F, Cheng L, Tang WJ, Wang XQ. A high neutrophil-to-lymphocyte ratio predicts hemorrhagic transformation of large atherosclerotic infarction in patients with acute ischemic stroke. Aging (Albany NY). 2020;12(3):2428\u201339.","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"1060_CR39","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awx111","volume":"140","author":"L Mao","year":"2017","unstructured":"Mao L, Li P, Zhu W, et al. Regulatory T\u00a0cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke. Brain. 2017;140(7):1914\u201331.","journal-title":"Brain"},{"issue":"3","key":"1060_CR40","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.neuroscience.2008.07.044","volume":"158","author":"J Klehmet","year":"2009","unstructured":"Klehmet J, Harms H, Richter M, et al. Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience. 2009;158(3):1184\u201393.","journal-title":"Neuroscience"},{"issue":"5","key":"1060_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13230","volume":"50","author":"YL Yang","year":"2020","unstructured":"Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020;50(5):e13230.","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"1060_CR42","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1161\/STROKEAHA.120.032810","volume":"52","author":"P Jolugbo","year":"2021","unstructured":"Jolugbo P, Ari\u00ebns RAS. Thrombus composition and efficacy of thrombolysis and thrombectomy in acute ischemic stroke. Stroke. 2021;52(3):1131\u201342.","journal-title":"Stroke"},{"issue":"2","key":"1060_CR43","doi-asserted-by":"publisher","first-page":"H558","DOI":"10.1152\/ajpheart.01275.2004","volume":"289","author":"JM Gidday","year":"2005","unstructured":"Gidday JM, Gasche YG, Copin JC, et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol. 2005;289(2):H558\u201368.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"1060_CR44","first-page":"11","volume":"54","author":"S Torres-Riera","year":"2025","unstructured":"Torres-Riera S, Arboix A, Parra O, Garc\u00eda-Eroles L, S\u00e1nchez-L\u00f3pez MJ. Predictive clinical factors of in-hospital mortality in women aged 85 years or more with acute ischemic stroke. Cerebrovasc Dis. 2025;54(1):11\u20139.","journal-title":"Cerebrovasc Dis"},{"issue":"2","key":"1060_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70070","volume":"32","author":"A Arboix","year":"2025","unstructured":"Arboix A, Parra O. Tirofiban benefits the outcome of stroke patients with large artery atherosclerosis achieving full reperfusion and high NIHSS scores. Eur J Neurol. 2025;32(2):e70070.","journal-title":"Eur J Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01060-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:32:22Z","timestamp":1792143142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01060-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":45,"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01060-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"27 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lee H. Schwamm serves as a scientific consultant regarding trial design and conduct to Genentech and Member of steering committee (TIMELESS NCT03785678); consultant on user interface design and usability to LifeImage; and a member of a Data Safety Monitoring Boards (DSMB) for Penumbra (MIND NCT03342664). Marc Fisher serves as a consultant for Simcere USA and Lumosa; and a member of DSMB for Moleac. Manjun Hao, Yujie Ma, Lihua Wang, Aoming Jin, Zhe Kang Law, Bruce C. V. Campbell, Mark W. Parsons, Yuming Xu, Anding Xu, Zhixin Cao, Liyuan Wang, Shuangzhe Wu, Yongjun Wang, and Yunyun Xiong have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TRACE-III trial was approved by the Institutional Review Board at Beijing Tiantan Hospital, Capital Medical University (KY2021-129-03) and all participating centers, and was conducted in accordance with the ethical standards of the institutional research committee and the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants or their legally authorized representatives before participation.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}